Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2026)

Gyre Therapeutics (GYRE) reported Deferred Taxes of -$738000.0 for Q1 2026, down 286.39% year-over-year from $395949.4 in Q1 2025, and down 748.28% on a QoQ basis from -$87000.0 in Q4 2025.

Gyre Therapeutics (GYRE) has 4 years of Deferred Taxes data on file, last reported at -$738000.0 in Q1 2026.

  • Quarterly Deferred Taxes fell 286.39% year-over-year to -$738000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 88.18% YoY) and the FY2025 annual result came in at -$1.1 million, down 10.68% from the prior year.
  • Deferred Taxes eased to -$738000.0 in Q1 2026 per GYRE's latest filing, from -$87000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at -$87000.0 in Q4 2025 and bottomed at -$738000.0 in Q1 2026.
  • The 4-year median for Deferred Taxes is -$306500.0 (2024), against an average of -$334083.3.
  • The widest annual swing landed in 2025, when Deferred Taxes soared 85.3%; it then tumbled 286.39% in 2026.
  • Tracing GYRE's Deferred Taxes over 4 years: stood at -$403000.0 in 2023, then sank by 46.9% to -$592000.0 in 2024, then soared by 85.3% to -$87000.0 in 2025, then tumbled by 748.28% to -$738000.0 in 2026.
  • Per Business Quant, the three latest GYRE Deferred Taxes figures stand at -$738000.0 (Q1 2026), -$87000.0 (Q4 2025), and -$531000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -859,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -65.30 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 96.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 9.31 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -738,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -738,000.00
Dec 31, 2025 -87,000.00
Sep 30, 2025 -531,000.00
Jun 30, 2025 -300,000.00
Mar 31, 2025 -191,000.00
Dec 31, 2024 -592,000.00
Jun 30, 2024 -97,000.00
Mar 31, 2024 -313,000.00
Dec 31, 2023 -403,000.00
Sep 30, 2023 -199,000.00
Jun 30, 2023 -230,000.00
Mar 31, 2023 -328,000.00